Estrogen receptor beta in breast cancer

C. Palmieri, G. J. Cheng, S. Saji, M. Zelada-Hedman, A. Wärri, Z. Weihua, S. Van Noorden, T. Wahlstrom, R. C. Coombes, M. Warner, J. Å Gustafsson

Research output: Contribution to journalReview article

202 Scopus citations

Abstract

Estrogen is essential for normal growth and differentiation in the mammary gland. It also supports growth of approximately 50% of primary breast cancers. For this reason, removal of estrogen or blocking of its action with the anti-estrogen, tamoxifen, is the main treatment for estrogen receptor alpha (ERα)-positive tumors. In 1996, when oncologists became aware of a second ER, ERβ, there was some doubt as to whether this receptor would be of importance in breast cancer because the clinical consensus was that responsiveness to tamoxifen is related to the presence of ERα in breast cancer. Today we know that ERα and ERβ have distinct cellular distributions, regulate separate sets of genes and can oppose each other's actions on some genes. We also know that ERβis widely expressed in both the normal and malignant breast and that there are proliferating cells in the breast which express ERβ. In this review we summarize what is known about ERβ in breast cancer and examine the possibility that ERβ-selective ligands may well represent a useful class of pharmacological tools with a novel target, namely proliferating cells expressing ERβ.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalEndocrine-Related Cancer
Volume9
Issue number1
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Fingerprint Dive into the research topics of 'Estrogen receptor beta in breast cancer'. Together they form a unique fingerprint.

Cite this